ESG

A new study links daily mango and avocado to better vascular function, but what does the science—and the funding—really tell us about this fruity fix?

Fastest-growing US professional skincare brand HYDRINITY partners with VeraSeaCosmetics, bringing its regenerative science to France's $5.4B beauty scene.

A new OB/GYN-founded brand, Alubri, aims to elevate intimate care with clinical rigor, targeting the underserved perimenopause and menopause market.

With a new CRO and a major retail push, can the values-led organic drink company replicate its foodservice success against CPG giants? We investigate.

A new study of 500+ leaders shows most firms use AI superficially, facing intense ROI pressure, governance hurdles, and a growing talent gap.

As millions of solar panels near retirement, one Tennessee facility is turning a potential waste crisis into a sustainable manufacturing success story.

As phosphorus becomes a critical U.S. mineral, one firm's tech helps farmers cut fertilizer use by 50% while boosting profits and food security.

A new report on 1,800+ patients reveals a model for obesity care that preserves muscle, sustains weight loss, and may solve the GLP-1 cost crisis.

With a massive Series A, Alveus Therapeutics is advancing novel drugs aiming for more durable and higher-quality weight loss than current blockbusters.

Fresh off strong 2025 earnings, AtriCure will detail its growth strategy and innovative cardiac portfolio at a major life sciences conference.

After a pivotal trial failure, Alector will present its new strategy at a key health conference, focusing on its innovative brain-delivery platform.

With a promise of cellular renewal via exosomes, (plated) Skin Science is leading a biotech revolution. But can it navigate the hype and regulatory hurdles?

The maker of Wegovy and Ozempic announces a massive price cut. We explore what this means for patients, competitors, and the future of drug pricing.

Larimar Therapeutics' nomlabofusp receives Breakthrough Therapy Designation, paving an accelerated path for a potential disease-modifying treatment.

New data on MCO-010 gene therapy identifies ideal patients for Retinitis Pigmentosa, a key step as the one-time injection advances toward FDA approval.

With pivotal data imminent for its blockbuster hopeful AXPAXLI, Ocular Therapeutix faces a critical month of investor meetings amid commercial headwinds.

Swiss biotech AC Immune begins a human trial for an oral drug aiming to halt the chronic inflammation driving diseases like Alzheimer's and Parkinson's.

Maiden drilling at West Santa Fe reveals significant near-surface gold, sparking speculation of a low-cost, open-pit mine in the prolific Walker Lane.

As Autolus heads to key investor conferences, its strong AUCATZYL® sales and deep pipeline face scrutiny against mounting losses and a curious PR misstep.

A new report shows patients are rejecting 'overdone' looks for subtle, strategic care, driven by Ozempic, menopause, and a desire for authenticity.